Developer of innovative neurodegeneration small-molecules intended to establish a unique and effective platform for novel drug discovery. The company’s innovative neurodegeneration small-molecules leverages the clinically validated link between lysosome-based genetic disorders and neurodegenerative diseases, enabling health institutions to avail provision of new treatment options for patients with severe neurological diseases.
Acquired by Bial in October 2020.
